A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia

Open for enrollment

(956) 362-2396

Please contact us for more information or to learn if you are eligible to participate.

To evaluate the effect of tildacerfont in reducing GC use in subjects with CAH.

5323 S. McColl Rd., Edinburg, TX 78539

(956) 362-2390